Elion Therapeutics

Elion Therapeutics is a biotechnology company focused on transforming the treatment of invasive fungal infections. The company's seasoned leadership team represents more than 200 years of collective expertise in antifungal drug development, spanning large pharma, academia, and clinical medicine. Elion is built on the belief that mechanistic insights enable the targeted optimization of natural products, allowing the company to develop novel antifungal agents that address critical unmet needs in both efficacy and safety. The company's pipeline targets life-threatening invasive fungal infections, for which current treatment options are limited by toxicity, drug resistance, and narrow-spectrum coverage. Elion closed an $81 million Series B financing round in June 2024 and has continued advancing its antifungal pipeline.